Studies have demonstrated that alterations in the constitutive expression of PD‐L1 in cancer cells can be driven by various genetic abnormalities, including PTEN loss, PI3K or AKT mutations, EGFR mutations, MYC overexpression, CDK5 dysregulation, and PD‐L1 gene mutations or deletions [77]. Here, PTEN is linked to cancer.